Abstract
The objective of this phase II study was to evaluate the safety and effectiveness and the optimal dosage of gadoversetamide. Eighty-one patients underwent two complete MRI examinations of the head or spine between 1 and 5 days apart. Each received two different randomized intravenous doses of gadoversetamide, either 0.1,0.3 or 0.5 mmol/kg. Identical imaging parameters and injection rates were maintained. Baseline and follow-up hematologic and blood and urine chemistry tests were obtained. Vital signs were obtained at predetermined intervals. Seventy-three patients completed the study, for a total of 146 injections. No clincally significant or life-threatening adverse effects were noted, nor were clinically significant changes in vital signs or laboratory values attributable to the contrast agent observed. Gadoversetamide is a new non-ionic gadolinium chelate which, based on these preliminary studies, appears to be safe and effective over a wide range of doses for MRI of the head and spine
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Vogl TJ, Mack MG, Juergens M, et al (1994) MR diagnosis of head and neck tumors: Comparison of contrast enhancement with triple-dose gadodiamide and standard-dose gadopentetate dimeglumine in the same patients. AJR 163:425–432.
Sze G, Brant-Zawadski M, Haughton VM, et al (1991) Multicenter study of gadodiamide injection as a contrast agent in MR imaging of the brain and spine. Radiology 181:693–699.
Wagoner MV, O’Toole M, Quay SC (1990) Nonionic magnetic resonance imaging contrast agents. Clinical trial experience of safety, tolerance, and efficacy of gadodiamide injection. Invest Radiol 25:S39–S41.
Greco A, McNamara MT, Lanthiez P, Quay SC, Michelozzi G (1990) Gadodiamide injection: nonionic gadolinium chelate for MR imaging of the brain and spine — phase II–III clinical trial. Radiology 176:451–456.
Yuh TC, Engelken JD, Muhonen MG, Mayr NA, Fisher DJ, Ehrhardt JC (1992) Experience with high-dose gadolinium MR imaging on the evaluation of brain metastases. AJNR 13:335–345.
Yuh TC, Fisher DJ, Engelken JD, et al (1991) MR evaluation of CNS tumors: dose comparison study with gadopentetate dimeglumine and gadoteridol. Radiology 180:485–491.
Runge VM, Kirsch JE, Thomas GS (1991) High dose applications of gadolinium chelates in magnetic resonance imaging. Magn Reson Med 22:358–363.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Kuhn, M. et al. (1995). Injection of gadoversetamide, a new gadolinium chelate: ultra-high dose usage for MRI of the central nervous system. In: Takahashi, M., Korogi, Y., Moseley, I. (eds) Proceedings of the XV Symposium Neuroradiologicum. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-79434-6_259
Download citation
DOI: https://doi.org/10.1007/978-3-642-79434-6_259
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-79436-0
Online ISBN: 978-3-642-79434-6
eBook Packages: Springer Book Archive